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Origins and implications of neglect of G6PD
deficiency and primaquine toxicity in
Plasmodium vivax malaria
Kevin Baird
University of Oxford, UK and Indonesia
Most of the tens of millions of clinical attacks caused by Plasmodium vivax each year likely originate from
dormant liver forms called hypnozoites. We do not systematically attack that reservoir because the only
drug available, primaquine, is poorly suited to doing so. Primaquine was licenced for anti-relapse therapy
in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phos-
phate dehydrogenase (G6PD) with acute haemolytic anaemia. The standard method for screening G6PD
deficiency, the fluorescent spot test, has proved impractical where most malaria patients live. The blind
administration of daily primaquine is dangerous, but so too are the relapses invited by withholding
treatment. Absent G6PD screening, providers must choose between risking harm by the parasite or its
treatment. How did this dilemma escape redress in science, clinical medicine and public health? This
review offers critical historic reflection on the neglect of this serious problem in the chemotherapy of
P. vivax.
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Introduction
‘Doctors commonly get mixed up between
absence of evidence and evidence of absence’.
Nassim Nicholas Taleb
How humanity perceives a problem ultimately defines
the nature and urgency of the solutions collectively
applied to solving it. Drug-resistant Plasmodium
falciparum, for example, commands priority and
diligence in order to prevent loss of life due to failed
therapy of that dangerous infection.1 The community
of malariology undertakes vigorous efforts at
understanding and systematically monitoring that
problem in order to spare patients from poor
outcomes.2,3 Failing to monitor antimalarial drug effi-
cacy – and instead using drugs we hope still work, but
may not – would be reckless and irresponsible. The
life of the patient too often depends upon delivering
therapies that cure falciparum malaria.4 This evi-
dence-informed perception and appropriately vigorous
response has not been applied for patients infected by
Plasmodium vivax.
Monitoring efficacy of chloroquine against the
acute attack of vivax malaria is rarely undertaken.5
Endemic resistance in many areas was demonstrated
over two decades ago,6 and is now highly prevalent
across large swathes of Southeast Asia.7 Flawed
reasoning largely explains the lack of vigour in
monitoring drug resistance in P. vivax: although
poor therapies may result in illness, infection by
this benign species rarely causes loss of life. The
false perception of harmlessness in this species
eased the burden of responsibility to always deliver
therapies that work. The conspicuous differences in
management of the respective drug resistance pro-
blems in these two dominant Plasmodium species
reflect our perceptions of the differing consequences
of failed therapy between them.
In the case of P. vivax a second therapy, primaquine,
is required to kill dormant liver stages called hypno-
zoites. Those stages, absent in P. falciparum, later
awaken and provoke repeated clinical attacks of vivax
malaria.8 There is no systematic surveillance under-
taken to monitor the efficacy of this drug, despite
more than 60 years of continuous use. The failure to
gather evidence of sustained good efficacy of this
drug, like chloroquine, also stems from the perception
of relatively minor consequences with poor efficacy.
The provision of presumptive primaquine therapy
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against such attacks in non-immune travellers, for
example, has been viewed as optional.9–12 Providers
seem content to risk post-travel attacks rather than
offer primaquine therapy.13 Similarly, treating against
relapse in patients living in endemic areas was long
viewed as unnecessary – the 1981 treatment guidelines
for malaria from the World Health Organisation
(WHO) expressed, ‘It is doubtful if radical treatment of
vivaxmalaria is necessary if the patient lives in an endemic
area where transmission of the infection continues and
reinfection is likely’.14
When weighed against the threat posed by daily
primaquine in patients of unknown glucose-6-phos-
phate dehydrogenase (G6PD) status, the risk of later
clinical attacks by a non-threatening species seemed a
reasoned weighing of risk and benefit. Primaquine
causes a mild to severe acute haemolytic anaemia in
patients having an inborn deficiency of G6PD. This
highly diverseX-linked disorder affects over 400million
people and occurs at an average prevalence of 8% in
malaria endemic nations.15 Safety concerns demand
screening out patients deficient in G6PD prior to offer-
ing daily primaquine therapy, especially where clinical
monitoring is impractical. However, the only methods
available for doing so require laboratory skills, special
equipment, a cold chain for reagents and come at rela-
tively high cost.16 The inability to distinguish G6PD-
deficient from normal patients often results in all of
them being denied access to primaquine therapy. The
hypnozoite reservoir goes largely unchallenged, stream-
ing new clinical attacks and onwards transmission into
the human communities where it resides unmolested
by primaquine.17,18
The absence of evidence that these practices
actually caused injury or failed to mitigate harm
dominates among other factors likely explaining the
long persistence of poor access to safe therapy
against relapse. Testing the hypothesis of harmless-
ness in P. vivax, demonstrating health dividends in
withholding primaquine therapy, or proof of safety
in offering it without G6PD screening – all would
have offered materialised evidence of maximal benefit
with minimal harm, but such evidence was not devel-
oped and followed. Instead, we carried on in these
practices for over 60 years, apparently confident
that the long absence of contrary evidence somehow
affirmed the assumptions embedded within them.
But evidence of harm being done has emerged. That
evidence, reviewed here, provides a wholly newperspec-
tive on vivaxmalaria and itsmanagement, and a correc-
tive course is being vigorously advocatedwithin the field
of contemporary malariology. Understanding how this
very significantproblemstood for so longwithoutatten-
tion from the communities of medicine, science and
public health offers important historic insights inform-
ing future strategy on this and other human problems.
Pernicious and Not Benign
Discussion of the neglect ofP. vivax and itsmanagement
as a clinical andpublic health problem requires consider-
ation of the intrinsic harmless character erroneously
assigned to this species.19,20 The false dichotomy of
benign versus malignant malarias, represented by
P. vivax and P. falciparum, profoundly influenced con-
temporary malariology. Humanity naturally focussed
resources and energies on the ‘harmful’ species as a
greater priority than the ‘harmless’ species – a focus
engendered by P. falciparum also being less complex
and amenable to laboratory cultivation. P. vivax
seemed tooffer relativelyminor scientific andhealthdivi-
dends as returns on the extraordinary difficulty of both
basic research and successful treatment. Plasmodium
falciparum has overwhelmingly dominated research
agendas and outputs, to include both basic research
papers and translational products of research (Fig. 1).
Recent evidence informs a view of P. vivax as
pernicious rather than benign. An attack by
P. vivax causes agonising daily paroxysms often
accompanied by intractable nausea and vomiting,
headache, myalgia and profound asthenia.21 Most
patients are incapacitated for several days, even
with prompt diagnosis and effective treatment.
Chronic or repeated attacks by this parasite very
often lead to severe anaemia and risk of death.22,23
Just a few weeks of untreated infection in
non-immune adults drives haemoglobin levels below
5 g/dl,24 and young children in endemic zones are
especially susceptible to threatening severe
anaemia.25 Severe illness with acute infection
includes lung injury with respiratory distress,
kidney injury with renal dysfunction, hepatic
dysfunction and jaundice, seizures/delirium/coma,
severe thrombocytopaenia or circulatory
collapse.26,27 The risk of patients in the hospitals of
endemic settings being classified as severely ill with
a primary diagnosis of vivax malaria approximates
that in patients with falciparum malaria in the same
hospitals, about 10%.28,29 In hospitals anywhere,
the risk of death as an outcome with severe disease
and a primary diagnosis of malaria is statistically
indistinguishable between the two species, typically
ranging between 5 and 15%.28–30 Those severe
morbidity and mortality rates perhaps exclude from
the denominators studies carried out where local
P. vivax may be relatively non-threatening. Variable
virulence linked to strain identity or access to good
healthcare is known in this species.29 Nevertheless,
no studies have affirmed the broad and deeply
entrenched notion of P. vivax as intrinsically benign or
harmless, and poor access to limited healthcare services
is the rule where endemic vivax malaria occurs.
The above synopsis of the clinical consequences of
infection by P. vivax only recently emerged. Contrast
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that current assessment with S.F. Kitchen’s of 1949,
‘this parasite [P. vivax ] does not appear to possess,
in the sense that P. falciparum does, any attributes
that induce perniciousness. It is therefore difficult to
understand how it can, in the absence contributory
factors, cause dangerous clinical states’.24Acknowledging
that error lays the foundation for understanding the
specific problem of the neglect of primaquine
and G6PD deficiency as a serious obstacle to
effective therapy.
Benign Neglect
Alphonse Laveran described the protozoan aetiology
of malaria in 1880, and by 1895 the three principal
species of human plasmodia were described taxono-
mically. P. falciparum, P. vivax and Plasmodium
malariae became objects of study in establishing
taxonomic order in clinics applying a pre-Laveran
taxonomy based on clinical manifestations.24 The
clinical taxonomy recognised and exploited clear
distinctions in the course and consequences of what
malariologists of that era understood to be distinct
malarial diseases.31 Some of those classes of malaria
were very rarely fatal, while others were often lethal.
The notion of benign and malignant malarias long
predates knowledge of species identities.
Today, we recognise that all species of plasmodia
infecting humans usually cause a relatively mild and
non-threatening illness or even none at all (with
naturally acquired immunity). Nonetheless, each of
the five known species infecting humans – now includ-
ing Plasmodium ovale and Plasmodium knowlesi,32,33
the latter being a zoonosis and very often threatening –
may also turn deadly. But this understanding is recent,
Figure 1 Graph illustrating the percentage of citations in books for Plasmodium falciparum and Plasmodium vivax
from 1900 to 2008 by use of the tool at http://books.google.com/ngrams (1A, top), and citation data from PubMed since 1960
(1B, bottom) taken from Ref. 86 published under Creative Commons license. These graphs reproduced from Ref. 28 with the
permission of Clinical Microbiology Reviews.
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and for most of the 125 years since the plasmodia infect-
ing us became known, we accepted species identity as
ordaining malignant versus benign courses and conse-
quences. A diagnosis of P. falciparum inspired fear and
dread, whereas P. vivax, P. malariae or P. ovale evoked
little concern regarding possible loss of life. This dichot-
omy profoundly shaped not only the science ofmalariol-
ogy, but also broader views of malaria as a global health
problem. The global malaria mortality burden came to
be viewed as being caused almost entirely by a single
species of parasite (P. falciparum) on a single continent
(Africa) – and humanity focussed its ingenuity, energies
and resources on those.29
What many considered the definitive text of malar-
iology, Boyd’s two volume set published in 1949,
included chapters on the clinical course and conse-
quence of the four human malaria species24 (excluding
P. knowlesi, recognised as such only a decade ago34).
The contributing malariologists all had lived through
the transition from malaria endemic to non-endemic
North America and Europe, and then many of them
managed the Global Malaria Eradication Campaign
of the 1950s and 1960s. Although a global nadir in
endemic malaria occurred in the mid-1960s
(exempting most of sub-Saharan Africa), the WHO
abandoned the campaign in 1969 as untenable.35
Malariology in most developed nations contracted
or vanished with local endemic transmission, and
few prote´ge´s were cultivated. Many of the experienced
malariologists of that era retired in the belief
that malaria would soon be eradicated. We may
thus appreciate Boyd’s text and others like it as key
links to what had been nearly lost wisdom in
malariology.
The global resurgence of malaria that began during
the 1970s eventually mobilised a new generation of
malariologists in the 1980s and 1990s who possessed a
great deal less direct experience. They turned to the
knowledge recorded in texts like Boyd’s. The title of
that text certainly invited viewing it as authoritative:
Malariology: a Comprehensive Survey of All Aspects of
This Group of Diseases from a Global Standpoint, as
did its extraordinary richness of technical detail across
the promised broad array of the field.
In the chapter on the clinical course of P. vivax in
humans, Kitchen described the species as intrinsically
benign, biologically incapable of doing serious
harm.24 He did so almost exclusively on the basis of
the consistency of relatively very low-grade infection
of peripheral blood; compared to P. falciparum;
typicallyv10 000/ml versusw100 000/ml in his exper-
imentally infected study subjects being thus treated
for neurosyphilis. Kitchen understood the fastidious
and obligatory invasion of reticulocytes by merozoites
ofP. vivax, versus the promiscuous invasion of any red
blood cell by those of P. falciparum. This created the
impression of a self-limiting and benign infection
versus a limitless replication in malignant fashion
that marked infection by P. falciparum in his subjects.
The dogma of benign versus malignant tertian
malarias from the pre-Laveran classifications had
been seemingly verified by Kitchen. However,
no consideration had been given to the possibility of
the bulk of harmful biomass of P. vivax occurring
exterior to the vascular sinuses and being undetectable
by examination of peripheral blood smears.29
No direct evidence informed that hypothesis of an
inherently harmless species, and Kitchen rejected or
set aside the evidence suggesting otherwise. Harmless-
ness in vivax malaria thus became a tenet of modern
malariology.
Research on vivax malaria became sharply limited
after the 1950s. It would not begin to rebound, as did
research on P. falciparum beginning in the 1970s,
until after the new millennium. During all this time,
up to the present day, primaquine stood as the only
therapy against relapse. The inability to provide it
safely without G6PD screening failed to register as
a problem in need of solving. Understanding that
failure requires examining the genesis of primaquine
therapy.
Discovery of Anti-Relapse Therapy and G6PD
Deficiency
The false perception of inherent harmlessness in
P. vivax does not fully account for the inadequacy of
primaquine against relapse. The sections to follow
retrace the discovery and development of anti-relapse
therapy and the linked discovery of G6PD deficiency.
This history more directly informs the quest to under-
stand the genesis of the exceedingly poor effectiveness
of primaquine and its acceptance as a satisfactory
therapeutic solution for P. vivax for over 60 years.
Emergence of anti-relapse therapies
Excepting the herbal remedy for fevers later found to
contain artemisinin, until the early twentieth century
quinine represented the only therapeutic agent against
acute malaria. Although in the late nineteenth century
a synthetic aniline dye (methylene blue) cured acute
malaria (in just two research subjects), no serious
attempt at discovery of synthetic antimalarials was
undertaken before about 1910. In that era, the
Dutch consolidated their global monopoly on quinine
production on Java in the East Indies (Indonesia).
German scientists at the I.G. Farben Laboratories
challenged that monopoly with a suite of synthetic
antimalarial drugs. They began their search with
methylene blue, systematically substituting various
moieties to that core molecule and observing the
effects on therapeutic activity (against Plasmodium
reticulum in a Javanese finch model). This
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revolutionary work birthed medicinal chemistry and
the methodology for discovery of chemotherapeutic
agents.36,37
The first synthetic drug they brought to market
(in 1927) was an 8-aminoquinoline they called plasmo-
chin, later also known as pamaquine. They marketed
it as therapy for the acute attack, but the drug soon
earned a reputation as being dangerous, especially in
non-Caucasians.38–40 There was no understanding of
G6PD deficiency and 8-aminoquinoline haemolytic
toxicity in that era, nor was there certain knowledge
of latent liver stages of the plasmodia. When
practitioners augmented lower doses of pamaquine
with quinine, they aimed only at mitigating the
toxicity of pamaquine for therapy of the acute
attack. Patients thus treated for acute vivax malaria,
it was noticed, were much less likely to suffer delayed
attacks (relapses).41 Radical cure of vivax malaria had
thus been unwittingly invented. Understanding of the
specific activity of pamaquine against dormant
liver stages came much later. None of the synthetic
antimalarials seriously challenged the primacy of
quinine until events denied access to it.
Synthetic antimalarials and the Pacific War
In March 1942, the Imperial Japanese seized the
Netherlands East Indies, including Java, where 95%
of the global supply of quinine originated. The
Allies rallied to manufacture a synthetic blood
schizontocide called atabrine (or mepacrine, or
quinacrine) and pamaquine, suspending the I.G.
Farben/Bayer patent rights on those compounds.
Figure 2 illustrates the chemical relatedness of these
compounds, along with those of chloroquine and
primaquine. The Allies faced a very serious malaria
threat in the Pacific and the loss of access to quinine
impelled them to aggressive corrective action.
Threat of war spurred creation of the Board for
Coordination of Malaria Studies in 1941 at the
National Science Foundation in Washington, DC.
That board mobilised enormous financial, scientific
and clinical capital into antimalarial drug discovery
and development.42
In the early 1940s, malariologists understood the
phenomenon of relapse in P. vivax and the likely
involvement of a dormant tissue stage (liver and
hypnozoite as yet unknown as that tissue and stage),
along with the apparent activity of pamaquine against
those hypothesised latent tissue stages. The Allied war
planners understood the threat relapse posed, not only
to their troops in the field, but they also worried about
several million returning troops reintroducing
endemic malaria transmission to a North American
continent on the verge of eliminating it. Attacking
the dormant tissue stage was a very high priority,
and they attempted doing so with an untried combi-
nation of drugs for radical cure: atabrine (blood
schizontocide) and pamaquine (tissue schizontocide).
An unexpected drug–drug interaction exacerbated
the already marginal safety of pamaquine,43 and in
1943 the US Surgeon General ordered pamaquine
not be used with atabrine against relapse.44 The ability
to treat against relapse was lost at the moment of
greatest need.
Discovery of primaquine
The Board for the Coordination of Malaria Studies
resolved to address this threatening problem and
mobilised a search for a less toxic option to
pamaquine.45 They ordered that only 8-aminoquino-
lines be considered in that search in order to assure
speedy delivery of an agent certain to prevent relapse.
In their aim of mitigating the toxicity of pamaquine,
they had no understanding of the central role of
G6PD deficiency in that problem. Their preclinical
screening of 8-aminoquinoline candidates consisted
of classical toxicity studies in rats and dogs, none
being relevant to the core toxicity problem of
innate susceptibility to acute haemolytic anaemia in
some patients. About 2-dozen candidate compounds
were thus selected and went to clinical trials in
prisoner volunteers. The effort outlasted the war,
and in 1950 primaquine emerged as having a slightly
higher therapeutic index than pamaquine and other
8-aminoquinoline candidates.46
The original problem of pamaquine interaction
with atabrine had been rendered irrelevant by the
‘discovery’ of chloroquine licenced for the treatment
of acute malaria in 1946 – that was another
I.G. Farben compound (they called it resochin) lifted
by the Allies. Coatney detailed the extraordinary
intrigue-filled tale of its development.47 In 1952,
primaquine was licenced in the USA for radical cure
Figure 2 Chemical structures of the synthetic antimalarials
created by I.G. Farben/Bayer in Germany during the 1920s
and 1930s (pamaquine, mepacrine and chloroquine) and
primaquine from the US Army during the 1940s.
Reproduced from Ref. 6 with the permission of Clinical
Microbiology Reviews.
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of vivax malaria in combination with chloroquine for
terminating the acute attack. The developers knew of
the phenomenon of ‘primaquine sensitivity’ in their
prisoner volunteers. Working with pamaquine and
quinine during the war, they found that the effective
total dose could be distributed over 14 days with
good efficacy against relapse and mitigating the
observed haemolysis among the pamaquine-sensitive
subjects,48 predominantly African Americans.
In this history one may grasp that the chemical
search leading to primaquine excluded the universe
of chemical possibilities beyond the 8-aminoquino-
lines, and it could not select against the key toxicity
problem with that class of compounds. No model
of latent hypnozoites guided the process of winnow-
ing candidates for superior therapeutic activity prior
to trials in humans. This war-spurred and sharply
limited drug discovery endeavour delivered a flawed
and deficient product (one scarcely different from
pamaquine in structure, Fig. 2), and one that
remains the only therapy against relapse 63 years
later. Misconstruing the seemingly non-threatening
treatment largely explains the view of primaquine
as a satisfactory solution for radical cure of vivax
malaria, then and in the decades that followed.
Discovery of G6PD deficiency
Most of the clinical trials leading to discovery of prima-
quine were conducted at the Stateville Penitentiary
in Illinois using inmate volunteers.49 Investigators
noted haemolytic sensitivity to 8-aminoquinolines
(all of them evaluated) among African-American
but not Caucasian prisoner volunteers.50
Meticulous clinical and laboratory investigation led
to the identification of deficiency in erythrocytic
G6PD as the basis of primaquine sensitivity in
1956.51 In that year, primaquine had already been in
clinical use for over 5 years, principally among US
troops in combat on the Korean Peninsula. The US
military developers of primaquine had adapted to
administering the therapy without knowledge of
G6PD deficiency. They had already experienced the
15 mg daily dose of primaquine for 14 days, so
effective against Korean P. vivax strains, as being
sufficiently well tolerated by primaquine sensitive
soldiers. Screening for G6PD deficiency thus seemed
pointless and was not routinely done by the US
Army (until about 2006).
During the 1960s, primaquine therapy against
relapse was routinely administered without knowing
G6PD status of the patient. Providers were warned
to be alert to the risk of haemolytic anaemia and to
stop dosing with onset of signs. This was the US
Army dosing strategy developed before G6PD
deficiency was known, and it found global
application in WHO recommendations for radical
cure of vivax malaria. As late as 1981 the WHO
recommendation read, ‘Reports on large numbers of
patients treated with this regimen, even where G6PD
deficiency is quite common, indicate that this regimen
[15 mg daily for 14 days] is generally well tolerated
and that hemolysis, when it occurs, is mild and
self-limiting’.14 This recommendation effectively
refers to safety demonstrated by the absence of evi-
dence of harm rather than materialised evidence of
safety. The American experience with primaquine in
a handful of otherwise healthy G6PD-deficient
African-American men characterised as provoking a
‘mild and self-limiting’ haemolysis seemed universally
applicable. The safety of primaquine without G6PD
screening in broader human populations was
presumed rather than demonstrated.
The great diversity of G6PD deficiency was only
dimly understood in that era. Papers from the
mid- to late-1960s began reporting G6PD variants of
extreme sensitivity to primaquine relative to the
African A{ variant. Severe reactions requiring trans-
fusion, and some ending in death, appeared as case
reports in the literature.52–56 Experimental primaquine
challenge of subjects having theMediterranean variant
of G6PD deficiency affirmed relatively extreme
sensitivity to primaquine compared to A{.57–59
Epidemiologists and geneticists eventually surveyed
the diversity of G6PD deficiency, finding Africa and
the Americas to be relatively homogeneous; the
A{ variant dominated among the G6PD-deficient
people on those continents. In contrast, theMediterra-
nean variant dominated across southern Europe, the
Middle East, and through Iran, Afghanistan, Pakistan
and much of western India. In eastern India, a great
diversity of variants appears and extends across
the rest of tropical Southeast Asia (Fig. 3).15,60,61
The majority of these Asian variants more closely
resemble Mediterranean variant with regard to
residual enzyme activity being very low (Fig. 4).15
The reality of serious hazard with offering primaquine
without knowingG6PD status, especially in Asia, thus
became recognised and acknowledged by the early
1980s.62 The WHO malaria treatment guidelines of
2010 expressed, ‘In patients with the African variant
of G6PD deficiency, the standard course of primaquine
therapy produces a benign and self-limiting anemia.
In the Mediterranean and Asian variants, hemolysis
may be much more severe’.63
Therapy without G6PD Screening
Advocates of primaquine therapy without G6PD
screening point to the lack of evidence demonstrating
harm being done. An exhaustive review aimed at
demonstrating safety of a single gametocytocidal
dose of primaquine uncovered little evidence of risk
of death with any primaquine therapy and estimated
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such at 1 in 621 428 treatments.64 As noted in that
report, however, reliance upon evidence passively gath-
ered through conspicuously poor pharmacovigilance
systems should be cautiously considered. The hypoth-
esis of relative safety in primaquine therapy without
G6PD screening requires direct evidence that does not
yet exist. Instead, the available evidence (described
above) demonstrates the capacity for serious harm
with therapeutic dosing of G6PD-deficient patients.
The diversity of G6PD deficiency is key to analys-
ing evidence of primaquine safety. In the discovery of
G6PD deficiency and its diversity, two broad
phenotypes emerged: mildly primaquine sensitive,
and exquisitely sensitive, those being represented by
the African A{ and Mediterranean variants,
respectively. Figure 5 best represents the stark
distinction between them regarding residual levels
of G6PD activity in red blood cell populations.65
The A{ red blood cells begin life with only slightly
diminished G6PD activity that then more sharply
declines as they age, both relative to G6PD-normal
red blood cells. This largely explains the phenom-
enon of acquired tolerance to daily primaquine
dosing in A{ variant, as illustrated in Fig. 6.66
Primaquine destroys older red blood cells in the
first few days of dosing, and these are replaced by
young red blood cells capable of surviving
primaquine challenge. As may also be seen in
Fig. 5, however, Mediterranean variant offers no
red blood cell subpopulations capable of surviving
primaquine challenge. It is known that even reticulo-
cytes of this variant are susceptible to destruction
by primaquine. Acquired tolerance of the drug in
A{fashion is thus impossible among Mediterra-
nean-like variants, and each new primaquine dose
deepens the haemolytic crisis.56,58,67
Patients having Mediterranean-like G6PD
deficiency would not likely survive a full 14-day
regimen of primaquine, and death is a confirmed
outcome in some patients.68–70 Onset of conspicuously
dark urine after three or four daily doses of primaquine
would serve to alert patients and their providers of
serious trouble and to then cease dosing. This obvious
sign, and understanding its relationship to the drug,
has surely saved many patients from poor outcomes.
However, malaria patients in the rural endemic tropics
may not grasp that their deteriorationwith progressive
haemolytic crisis (weakness, shortness of breath and
jaundice) is due to primaquine rather than the
recent illness diagnosed as malaria. They may stead-
fastly continue dosing with the drug provided to
them to combat that malaria, mistaken in the belief
that malaria still sickens them. They also may not
notice the darkening of urine. The toilets and latrines
of the rural tropics offer every opportunity to miss
onset of dark urine – unlit pit outhouses represent
the rule and clear water-filled toilet bowls in
brightly lit rooms the exception. Offering anti-relapse
primaquine therapy without knowledge of G6PD
status should be acknowledged as an intrinsically
dangerous practice to be undertaken only under close
clinical supervision. The dominant policies guiding
primaquine therapy, however, seem rooted in the
‘mild and self-limiting’ dogma of the 1960s (Fig. 7).
The Threat of Relapse
While primaquine therapy for unscreened patients
may be dangerous, so too is withholding that
treatment. There is no alternative hypnozoitocide,
only a stark choice between risk of haemolysis or
recurrent clinical attacks. In a weighing of risk and
benefit that includes a harmless clinical attack or
Figure 3 Map illustrates the diversity of common variants of G6PD deficiency in eastern Asia and dominance of Mediterra-
nean variant in western Asia. Reproduced from Ref. 60 published under Creative Commons license.
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two, few would opt for risking primaquine therapy.
However, today we understand that repeated attacks
of vivax malaria pose a serious threat to the health
and life of patients. This reality greatly deepens the
primaquine/G6PD deficiency-relapse dilemma, and
examination of the threat posed by hypnozoites
informs weighing of risk and benefit.
The risk of relapse per se assignsweight of probability
and frequencyof subsequent clinical attack, each in turn
bearing upon riskof poor clinical outcomeandonwards
transmission. Acknowledging the great diversity of
relapse behaviours among P. vivax strains across
regions71 (Fig. 8), the focus here is upon the worst-
case scenario of Chesson-like P. vivax that occurs in
Southeast Asia and the Southwest Pacific. These para-
sites very quickly cause relapse in almost all patients,
and do so multiple times at about 2-month intervals.
In contrast, among strains from India or Korea, for
Figure 4 Maps illustrate geographic distribution of crude estimates of risk related to primaquine dosing derived by consider-
ing severity of impaired G6PD activity phenotype. Reproduced from Ref. 14 published under Creative Commons license.
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example, relapse occurs in a minority of patients and
typically does so more than 6 months after the primary
attack.
The experimental challenge work on the Chesson
strain of P. vivax during the 1940s and 1950s left
an abundant literature on its relapse behaviours.72
The findings effectively mirrored those in American
soldiers naturally infected by P. vivax in the Pacific
War.73 Relapse occurred as soon as 17 days after
onset of patency of the primary attack, and by the
28th day more than one half of patients relapsed.
After 8 weeks almost all had relapsed. Most patients
or subjects then relapsed a second or third time, and
many went on to experience 10 or more relapses.
Contemporary studies affirm that older literature
regarding relapse behaviour by Chesson-like strains
of P. vivax. The majority of patients infected in
Thailand typically relapsed within 28 days of
patency,74,75 as was true among a cohort of Indonesian
soldiers infected in IndonesianNewGuinea (Papua).76
The incidence density of attack by first relapse in those
studies was approximately 5/person-year in the first
2 months following patency. Those patient subjects
were not permitted to relapse multiple times, but a
New Zealand woman infected in Papua New Guinea
in 2012 suffered five relapses within a year at
2-month intervals as a consequence of therapeutic
failure of primaquine (very likely caused by a
cytochrome P-450 2D6 polymorphism).77 Southeast
Asia and the Southwest Pacific harbour P. vivax
carrying very high risk of multiple clinical
attacks. In those regions residents mostly carry var-
iants of G6PD deficiency considered ‘severe’, that is,
relatively very low residual G6PD enzyme activity
(Fig. 4).
The co-occurrence of relatively aggressive relapse
behaviours and perhaps more virulent P. vivax with
relatively severe G6PD variants may not be simply
an unhappy coincidence. Two well known facts
regarding this parasite and host enzyme may be
mechanistically linked – (1) P. vivax invades only
reticulocytes; and (2) G6PD enzyme activity
naturally declines as red blood cells age, with highest
levels occurring in reticulocytes (as in Fig. 5). There
Figure 5 Data illustrating key variance in the extent to which G6PD activity may be impaired among variants. The x-axis,
‘Position in the Gradient (C.D.F.)’ represents fractions of red blood cells collected by ultracentrifugation, where the youngest
cells are to the left, and oldest cells to the right. The top three panels illustrate the proportion of red blood cells as reticulo-
cytes among G6PD-normal (panel A) and two subjects having either A 2 (panel B) or Mediterranean (panel C) variants of
G6PD deficiency. Panels G, H and I, illustrate relative activities of G6PD enzyme in the same age-dependent gradient.
Note the conspicuous distinction between A 2 and Mediterranean variants, where in the latter even reticulocytes suffer
severely impaired enzyme activity. In contrast, the youngest A 2 red cells have nearly normal activity. This difference largely
explains the ability of A 2 patients to develop tolerance to large doses of primaquine as in Fig. 6, whereas Mediterranean
patients do not. Reproduced from Ref. 64 with the permission of the Journal of Clinical Investigation.
Baird Implications of neglect of G6PD deficiency
Pathogens and Global Health 2015 VOL. 109 NO. 3 101
Figure 7 Primaquine treatment policies against relapse among endemic nations in 2014. Reproduced with permission of the
World Health Organization, Global Malaria Program, Geneva.
Figure 6 Graph illustrates development of tolerance to primaquine in three otherwise healthy African–American subjects
with A 2 variant of G6PD deficiency. After an initial haemolytic anaemia, reticulocytemia followed and in turn haematocrit
returned to normal. The subjects then maintained effective normal blood profiles despite receiving daily doses of 30mg
primaquine for 120days. Reproduced from Ref. 65 with permission of the Bulletin of the World Health Organization.
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may be host survival advantage in forcing malaria
parasites to live in a red blood cell cytosol deprived
of the detoxifying effects of G6PD activity (the sole
source of electrons for NADPz and oxidised
glutathione).78 Achieving this with P. vivax infection
would require reticulocytes having greatly reduced
G6PD activity (as in panel I of Fig. 5). If so, the
unhappy coincidence is the extreme vulnerability of
such red blood cell populations to destruction by
primaquine – the patients most likely to gain the
potentially life-saving benefits of primaquine therapy
against relapse may also be those most likely to suffer
serious harm by its use.
Primaquine therapy for such patients – infected by
the strains of parasites most likely to cause rapid
multiple relapses of deepening consequences, and
harbouring the most severely deficient G6PD
variants – without knowing G6PD status may be
the most extreme expression of this clinical and
public health dilemma. Risk of serious harm haunts
either decision. Solving the dilemma, however,
is relatively simple; screen out the G6PD-deficient
Figure 8 Map charts geographic variation in relapse behaviours by Plasmodium vivax among ecological zones and the
graph below illustrates the timing and frequency of relapse within each ecological zone. Reproduced from Ref. 70 published
under Creative Commons license.
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minority and freely treat the G6PD-normal majority.
Primaquine is a remarkably safe and well-tolerated
drug among non-pregnant G6PD-normal patients79
and appears to retain superb efficacy against relapse
even against Chesson-like strains.76
Solving the Primaquine-G6PD Deficiency
Dilemma
The gold standard for screening patients for G6PD
deficiency has been the fluorescent spot test since
the mid-1960s.80 Although relatively simple and inex-
pensive by the standards of most modern clinical lab-
oratories, the test suffers several drawbacks
precluding routine use where the vast majority of
malaria patients obtain treatment. The kit requires
a cold chain for reagents, specialised equipment
(incubator, pipettor and source of ultra-violet light)
and laboratory skills. At about USD4/test, it is pro-
hibitively expensive in the rural tropics. The many
complex factors explained in this review account
for the lack of impetus to solve this problem with a
screening kit suited to the impoverished rural tropics.
Over the decades, no research-funding agency put
point-of-care G6PD diagnostics on its agenda. The
problem would eventually be addressed by entrepre-
neurial initiative and capital. In the past 5 years,
two companies developed point-of-care G6PD
diagnostic devices; CareStartH G6PD from Access-
Bio2 (Somerset, NJ, USA);81,82 and BinaxNOWH
G6PD from Alere2 (Waltham, MA, USA).83,84
The latter kit suffers the drawbacks of strict tempera-
ture limitations (testing above 25uC may be invalid)
and relatively high cost (about $15/test). The kit
from AccessBioH performs well at ambient tempera-
tures and costs only $1.50/test. Each is relatively
simple to perform and delivers a result in about
10 minutes.
Rolling out any G6PD diagnostic device for routine
use at the periphery of healthcare in the endemic rural
tropics may finally unleash the enormous therapeutic
and public health benefits of primaquine without caus-
ing harm. That task is by no means trivial, both in
terms of finance/logistics and training/quality assur-
ance. Nonetheless, there may be few other means of
greatly accelerating the control and elimination of
P. vivax. Moreover, doing so lays the foundations for
safe introduction of the single-dose 8-aminoquinoline
therapy called tafenoquine, a product now approach-
ing regulatory registration and clinical availability.85
That product will also require excluding G6PD-
deficient patients in order to realise its enormous prom-
ise as a new tool against vivax malaria.
Evidence demonstrates that the failure to prevent
relapse incurs risk of serious illness and death
with vivax malaria, as evidence demonstrates that
treating the unscreened incurs risk of serious harm
caused by primaquine. Robust G6PD diagnostic
devices at the point of care would largely solve this
dilemma and greatly mitigate risk of fatal outcomes
provoked by the parasite or its treatment. Humanity
should muster the resources and energies needed to
implement those devices as an essential element of
routine care for malaria. Chemotherapeutic or
chemo-preventive strategies for patients who cannot
receive primaquine (G6PD-deficient, pregnant
women and infants) should also be conceived,
optimised and validated.
Critical Reflection
Malariology virtually abandoned research on P. vivax
over 60 years ago, apparently confident in the
conviction of harmlessness relative to P. falciparum,
and content with the chloroquine–primaquine
chemotherapeutic solution for it. No evidence
emerged demonstrating P. vivax as dangerous and
evidence seeking to prove the hypothesis of harmless-
ness was not pursued. This also occurred with the
G6PD deficiency-primaquine problem – the absence
of evidence of harm after already widespread use of
the drug overruled laboratory and clinical studies
pointing to the potential for serious harm with
Mediterranean-like variants of G6PD deficiency.
Today, evidence and acknowledgement of these
problems, along with new technical solutions, now
offer the promise of correction of course. Patients
suffering acute P. vivax, especially repeated bouts
due to untreated hypnozoites, are today acknowl-
edged to be at risk of severe and fatal illness with
inadequate treatment. This understanding alone
substantially improves the likelihood that such
outcomes will become rare as a result of spurring
the implementation of much more aggressive and
effective control, prevention, diagnosis and treatment
practices. That includes impelling the achievement of
vastly improved access to safe primaquine therapy by
point-of-care G6PD devices at the periphery of care.
The primary lesson in these events and the thinking
contemporary to them demonstrates the peril in not
developing and following materialised evidence. This
is the core process of the scientific method, and in
not applying it we risk actions based upon fallacy.
In the instance of primaquine and G6PD deficiency
in therapy of P. vivax malaria, we indeed seemed
inclined to the confusion alluded to in Taleb’s quote
at the opening of this paper – the absence of evidence
construed as evidence of absence guided strategy and
practice. The assumptions embedded within those
practices proved wrong and indeed led to misunder-
standing and error. Over the decades, consequences
have very likely accumulated – unnoticed and
unexamined morbidity and mortality caused by the
parasite or its treatment with primaquine. Those
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may finally cease with assurance of safe delivery of
primaquine to patients in need of it spurred by the
materialised evidence informing the necessity and
urgency of doing so.
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